Trial Profile

A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Oct 2023 Results (n=42) assessing safety of AG019 as monotherapy and in combination with teplizumab in recent-onset type 1 diabetes patients, published in the Diabetologia..
09 Nov 2021 Status changed from active, no longer recruiting to completed.
09 Aug 2021 According to a Precigen Inc media release, additional data from trial will be presented at the European Association for the Study of Diabetes (EASD) 57th Annual Meeting and will be presented by Chantal Mathieu.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com